ロード中...
Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma
Lenvatinib was recently approved as a novel first-line molecular targeted agent (MTA) for treating hepatocellular carcinoma (HCC). The importance of relative dose intensity (RDI) has been shown in the treatment of various types of cancers. However, RDI may not accurately reflect the treatment intens...
保存先:
| 出版年: | Cancers (Basel) |
|---|---|
| 主要な著者: | , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7016578/ https://ncbi.nlm.nih.gov/pubmed/31877859 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12010049 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|